Placulumab is a human monoclonal antibody designed for the treatment of inflammatory diseases.[1]

This drug was developed by Teva Pharmaceutical Industries, Inc. As of 2012, development of placulumab has been discontinued.[2]

References

  1. ^ Statement On A Nonproprietary Name Adopted By The USAN Council - Placulumab, American Medical Association.
  2. ^ Antoniu SA (November 2013). "Discontinued drugs for pulmonary, allergy, gastrointestinal, arthritis (2012)". Expert Opinion on Investigational Drugs. 22 (11): 1453–64. doi:10.1517/13543784.2013.836489. PMID 24024675.


Allikas: http://en.wikipedia.org/wiki/Placulumab
No tags for this post.